Skip to main
KZR

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences has shown an improvement in investor confidence following the lifting of the partial clinical hold for its product candidate Zetomipzomib (KZR-616) in the treatment of autoimmune hepatitis (AIH), indicating a positive risk-benefit profile for this indication. The potential full removal of the clinical hold for lupus nephritis (LN) is expected to significantly enhance investor sentiment and could facilitate the resumption of development efforts, broadening the therapeutic applications of the drug. Overall, these developments indicate a promising trajectory for Kezar Life Sciences’s pipeline, suggesting a favorable commercial outlook as the company aims to address unmet medical needs in both autoimmunity and cancer.

Bears say

Kezar Life Sciences is currently facing significant challenges related to its clinical-stage pipeline, particularly with Zetomipzomib (KZR-616) and KZR-261, which may affect its future revenue prospects and market position in the competitive biotechnology landscape. The company's financials indicate high research and development expenditures without a corresponding increase in successful product development or partnerships, leading to concerns about financial sustainability. Additionally, the ongoing need for substantial capital to fund clinical trials may dilute shareholder value and hinder the company's ability to achieve timely product commercialization.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.